- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2014 (IV) and recently launched subcutaneously (Entyvio Pen). Biosimilar entry is the main future risk, with Alvotech's AVT16 BLA accepted for FDA review as of June 2026 and AVT80 BLA accepted in August 2026.
- Why 4/10
- ENTYVIO is already approved and marketed; there is no pending PDUFA, FDA advisory committee, or registrational-trial readout for this drug in the next 12 months. All recent catalysts (Phase 4 VERDICT data, raised guidance) have already occurred. The next hard catalyst would be a biosimilar approval decision or patent litigation ruling, neither of which has a confirmed date, so the binary event risk is minimal in the near term.
With the VERDICT Phase 4 data already released (October 19, 2026) and no upcoming FDA decision or pivotal readout for ENTYVIO itself, the next catalysts for TAK shareholders are the biosimilar patent litigation outcomes against Alvotech, Polpharma, and Samsung, plus quarterly sales trends. Litigation timelines are uncertain, making the near-term binary low for this specific drug.
Price Chart
Executive Summary
ENTYVIO (vedolizumab) is Takeda's blockbuster biologic for ulcerative colitis and Crohn's disease, first approved by the FDA in 2014 and now available in both intravenous and subcutaneous (Entyvio Pen) formulations. It is a key growth driver for Takeda, a diversified global pharma company. In October 2026, positive Phase 4 VERDICT data showed that treating to a disease-clearance endpoint reduced UC complication risk by about 67%, boosting the drug's clinical differentiation. The main overhang is biosimilar competition: Alvotech has two BLAs (AVT16 for IV, AVT80 for SC) under FDA review, and Takeda has filed patent lawsuits against Alvotech, Polpharma, and faces IP challenges from Samsung. With no upcoming regulatory decision for ENTYVIO itself, the drug's commercial trajectory depends on share protection from patents, market growth, and the pace of biosimilar entry.
How It Works
ENTYVIO is a biologic (monoclonal antibody) that works like a gut-specific traffic cop. It binds to a specific protein on immune cells (alpha4-beta7 integrin) that would normally allow those cells to travel from the bloodstream into the gut tissue. By blocking this interaction, ENTYVIO prevents inflammatory white blood cells from entering the gut lining, reducing inflammation in ulcerative colitis and Crohn's disease while largely leaving the rest of the immune system alone.
Trial Status
Phase 4 VERDICT trial results announced October 19, 2026, showed a 67% relative risk reduction in UC complications with a disease-clearance treatment strategy. Pediatric Phase 3 and Phase 2 studies have completed.
The Two-Sided Case
Upcoming Catalysts
- Biosimilar patent litigation outcomes: BPCIA lawsuits against Alvotech and Polpharma Biologics
- FDA review decisions on Alvotech's AVT16 (IV) and AVT80 (SC) biosimilar BLAs
- Quarterly ENTYVIO sales performance in Takeda earnings reports
Source Filing
The SecBot filing or press-release report that triggered this drug report:
TAKEDA PHARMACEUTICAL CO LTD 6-K TAK ·Originating report